secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001104659-26-043497
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma announces $10M PIPE (up to $60M with warrants) to fund UK flu challenge trial
--------------------------------------------------------------------------------

- Upfront gross proceeds of $10M from sale of ~5.98M shares at $1.6730/share; warrants could add $50M.
- Proceeds to advance influenza program tivoxavir marboxil through Phase 2a human challenge trial in UK.
- Warrant tranches: Series A ($10M upon MHRA approval), Series B ($10M post-data + shareholder OK), Series C ($30M, 3-year term).
- Lead investor Sirenia Capital Management; Cantor Fitzgerald lead placement agent; closing expected April 16, 2026.
- Company to file resale registration statement within 30 days of closing; shareholder meeting required for Series B/C warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926043497/0001104659-26-043497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926043497/tm2611843d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-043497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer